Gilead, Royalty Pharma pay Emory for Emtriva royalties
Executive Summary
Gilead Sciences and Royalty Pharma have purchased from Emory University the royalty interest associated with worldwide net sales of Emtriva (emtricitabine) for $341.25mm (65%) and $183.75mm (35%), respectively.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Royalty Sale
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice